search

Pharming Group NV (PHAR)

OverviewChartFinancialsStatisticsEarningsInsider transactionsETFsNews

News

Real-time news feed aggregating press releases, regulatory filings, and global media coverage for a single company, filterable by date range, relevance score, and sentiment classification. Each article is tagged with company-specific and overall market sentiment — allowing investors to separate fundamental catalysts from broader market noise and monitor how the narrative around a stock is evolving over time.

Relevance *
40
Pharming Wins UK Approval for Joenja in Children Aged 4–11
Nov 6, 2026

Pharming Wins UK Approval for Joenja in Children Aged 4–11

Pharming Group has received UK regulatory approval to expand the use of its treatment, Joenja, to children aged 4-11 with Activated PI3K Delta Syndrome (APDS) who weigh at least 27 kg. This approval adds younger patients to the existing authorization for adults and adolescents aged 12 and older. The expanded treatment indication is expected to become available to eligible UK patients in February 2027, with Pharming planning to collaborate with the NHS to ensure patient access.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish